Oncology – Breast
20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.
26 Sep, 2022 | 12:00h | UTCNews Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet
Commentary on Twitter
20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA
— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.
7 Sep, 2022 | 12:31h | UTCNews Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
RCT | Sacituzumab Govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.
29 Aug, 2022 | 12:05h | UTC
Triple negative breast cancer: pitfalls and progress.
26 Aug, 2022 | 13:02h | UTCTriple negative breast cancer: Pitfalls and progress – npj Breast Cancer
Consensus Recommendations | Standardizing pathologic evaluation of breast carcinoma after neoadjuvant chemotherapy.
23 Aug, 2022 | 12:52h | UTC
Spindle cell lesions of the breast: a diagnostic algorithm.
23 Aug, 2022 | 12:51h | UTC
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
ASCO Guideline Update | Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative.
17 Aug, 2022 | 14:17h | UTC
RCT | Adjuvant oral ibandronate does not improve outcomes in postmenopausal women with estrogen receptor–positive breast cancer.
16 Aug, 2022 | 13:15h | UTCDaily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
New phase 3 trial of adjuvant bisphosphonates for ER+ eBC published on @JCO_ASCO.
1,116 patients randomized to ET +/- 3 years of ibandronate. No DFS benefit (HR 0.97, p=0.81). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.https://t.co/CxhZcTNLhU— Paolo Tarantino (@PTarantinoMD) April 21, 2022
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
9 Aug, 2022 | 12:20h | UTC
Commentary on Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction.
28 Jul, 2022 | 13:05h | UTC
Systematic Review | Taxane monotherapy regimens for treating recurrent epithelial ovarian cancer.
25 Jul, 2022 | 12:47h | UTC
RCT | Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.
21 Jul, 2022 | 13:25h | UTCPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone. https://t.co/5urffgHdFb pic.twitter.com/2GlmJuYZJz
— NEJM (@NEJM) July 20, 2022
RCT | Oral Paclitaxel plus Encequidar vs. intravenous Paclitaxel in patients with metastatic breast cancer.
21 Jul, 2022 | 12:24h | UTC
Commentary on Twitter
Oral Paclitaxel is an alternative treatment option to every 3-week paclitaxel with more neutropenic serious infections and less incidence and severity of neuropathy for patients with advanced or mBChttps://t.co/wNrLfs2myN pic.twitter.com/l3aWGhEdwU
— K Pavithran (@drkpavithran) July 21, 2022
RCT | Gemcitabine vs. Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
14 Jul, 2022 | 12:10h | UTC
Commentary on Twitter
Gemcitabine or nab-paclitaxel in combination with cisplatin as first-line treatment in patients with metastatic triple-negative breast cancer: results of a randomized phase 3 trial.https://t.co/RKZYdLRbHq#CancerResearch @natrescancer pic.twitter.com/CrCOCJ2HMu
— Nature Communications (@NatureComms) July 13, 2022
Long-term analysis of a Phase 2 RCT | Fulvestrant plus capivasertib vs. placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive, HER2-negative breast cancer.
11 Jul, 2022 | 11:48h | UTCNews Release: New phase of breast cancer drug trial provides fresh hope for patients with incurable disease – Cardiff University
M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.
7 Jul, 2022 | 12:17h | UTC
RCT: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer.
1 Jul, 2022 | 10:28h | UTCCommentary: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive
Commentary on Twitter
Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt
— Paolo Tarantino (@PTarantinoMD) June 28, 2022
ASCO Guideline Update: Biomarkers for systemic therapy in metastatic breast cancer.
29 Jun, 2022 | 11:40h | UTC
Commentary on Twitter
‼️ 🆕 @ASCO guideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡️ https://t.co/qAzT9WNKTF #bcsm #biomarkers @AngieDemichele pic.twitter.com/3WtAt8TK5w
— Journal of Clinical Oncology (@JCO_ASCO) June 27, 2022
Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.
29 Jun, 2022 | 10:59h | UTC
Cohort Study: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.
27 Jun, 2022 | 11:09h | UTCPrognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Is #HER2low a distinct BC subtype? Among >5000 pts from DFCI/Brigham, we found no relevant difference between HER2-low & HER2-0 BC. ER-exp determined disease behavior & was positively associated with HER2-low exp. Huge thanks to @stolaney1 & all coauthors!https://t.co/OfGT8LS2pH pic.twitter.com/uFxXGvOI8S
— Paolo Tarantino (@PTarantinoMD) June 23, 2022